German Health Data Providers Compared: Claims Data Access, GDNG Compliance and RWE Fit for Pharma Research
Germany has one of the most analytically valuable health data environments in Europe — and one of the most structurally
Outcome Prediction Models in Healthcare: Using RWD to Build Predictive Analytics
Here’s the version of predictive modelling in pharma that doesn’t get discussed enough in vendor conversations: the one where the
Outcome Prediction Models in Healthcare: Using RWD to Build Predictive Analytics Read Post »
Longitudinal Data Analysis in Pharma: What Makes a Dataset Fit for Purpose
Here’s a pattern we see repeatedly in the RWE programmes we advise on across Continental European markets: a company selects
Longitudinal Data Analysis in Pharma: What Makes a Dataset Fit for Purpose Read Post »
Phenotype Validation in Claims Data: The RWE Step That Determines Whether Your Study Stands or Falls
Here’s something we see consistently in the RWE programmes we advise on: teams invest months in study design, data access
Pan-European Real-World Data for Pharma: How to Navigate Fragmented Claims Data Across Pan-European Markets for Multi-Market Launch
Most RWE teams in pharma are fluent in US claims logic. They know Optum. They know IBM MarketScan. They know
Real-World Evidence Myths: 5 Things Pharma Teams Get Wrong About RWE, Claims Data and Study Design
Every year, pharma companies spend tens of millions of dollars on real-world evidence programmes that fail to deliver what was
Why Pharma Data Scientists Spend 70% of Their Time on Data Engineering — And How Analysis-Ready RWD Changes That
The pharmaceutical industry has reached an inflection point. Real-world evidence isn’t a nice-to-have anymore—it’s the foundation for every major strategic
Aggregated and Synthetic Insurance Data: What It Is, Why It Matters, and Where It is Used
If you’re leading market access, HEOR, or commercial analytics at a pharma or medtech company, you’ve probably hit this wall: